Stephanie Davis
Stock Analyst at Barclays
(1.24)
# 3,299
Out of 4,818 analysts
95
Total ratings
32.31%
Success rate
-12.97%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $172.84 | +7.04% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $35.45 | +26.94% | 3 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $8.20 | -39.02% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $52.40 | +43.13% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.13 | +14.19% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.45 | +34.83% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $8.65 | +119.65% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $286.27 | +1.30% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $19.57 | +22.64% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $133.69 | -0.52% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $29.92 | +93.85% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.78 | +7.91% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.15 | +404.71% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $220.25 | +13.05% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $23.27 | +24.62% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.90 | +392.75% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.87 | +55.46% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $215.78 | +7.98% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.66 | +364.48% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $83.45 | -8.93% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $172.84
Upside: +7.04%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $35.45
Upside: +26.94%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $8.20
Upside: -39.02%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $52.40
Upside: +43.13%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.13
Upside: +14.19%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.45
Upside: +34.83%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $8.65
Upside: +119.65%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $286.27
Upside: +1.30%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $19.57
Upside: +22.64%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $133.69
Upside: -0.52%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $29.92
Upside: +93.85%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.78
Upside: +7.91%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.15
Upside: +404.71%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $220.25
Upside: +13.05%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $23.27
Upside: +24.62%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $6.90
Upside: +392.75%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.87
Upside: +55.46%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $215.78
Upside: +7.98%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.66
Upside: +364.48%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $83.45
Upside: -8.93%